Natixis Has $9.78 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Natixis lessened its position in Edwards Lifesciences Co. (NYSE:EW) by 48.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 102,301 shares of the medical research company’s stock after selling 96,945 shares during the quarter. Natixis’ holdings in Edwards Lifesciences were worth $9,776,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tiemann Investment Advisors LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $222,000. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Edwards Lifesciences by 21,094.6% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 19,711 shares of the medical research company’s stock worth $1,884,000 after purchasing an additional 19,618 shares during the last quarter. Saturna Capital Corp increased its position in shares of Edwards Lifesciences by 5.2% during the 1st quarter. Saturna Capital Corp now owns 22,611 shares of the medical research company’s stock worth $2,161,000 after purchasing an additional 1,109 shares during the last quarter. Lake Street Advisors Group LLC increased its position in shares of Edwards Lifesciences by 36.2% during the 1st quarter. Lake Street Advisors Group LLC now owns 3,573 shares of the medical research company’s stock worth $341,000 after purchasing an additional 950 shares during the last quarter. Finally, Mirova increased its position in shares of Edwards Lifesciences by 440.6% during the 1st quarter. Mirova now owns 6,439 shares of the medical research company’s stock worth $615,000 after purchasing an additional 5,248 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the transaction, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the transaction, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 857 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total value of $73,359.20. Following the sale, the vice president now owns 23,890 shares of the company’s stock, valued at $2,044,984. The disclosure for this sale can be found here. Insiders sold a total of 81,099 shares of company stock worth $7,003,553 in the last ninety days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded down $27.25 during trading on Thursday, reaching $59.70. 45,810,475 shares of the company traded hands, compared to its average volume of 3,698,478. The company’s 50 day moving average is $89.12 and its two-hundred day moving average is $87.12. The firm has a market capitalization of $35.98 billion, a PE ratio of 26.20, a PEG ratio of 3.19 and a beta of 1.11. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. The firm had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.66 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on EW. Robert W. Baird lowered Edwards Lifesciences from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $102.00 to $70.00 in a research report on Thursday. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday, June 27th. Barclays boosted their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $105.00 to $75.00 in a report on Thursday. Finally, JPMorgan Chase & Co. lowered Edwards Lifesciences from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $105.00 to $72.00 in a report on Thursday. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $84.57.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.